Moderna Inc
NASDAQ: MRNA
$38.36
-$2.40 (-5.9%)
Closing Price on December 18, 2024
MRNA Articles
Vaccine maker Moderna has announced it is working on a new vaccine, and another COVID-19 treatment is getting hammered.
Published:
Here's a look at how August's most-discussed stocks on WallStreetBets performed in the month. Sometimes, talk is not cheap.
Published:
Friday’s top analyst upgrades and downgrades included BP, Cloudflare, Expedia, FireEye, Marathon Oil, Moderna, Pinduoduo, Vertex Pharmaceuticals and ViacomCBS.
Published:
COVID-19 vaccine maker Moderna, silver miner Hecla, and entertainment giant ViacomCBS are scheduled to report quarterly results before markets open Thursday morning.
Published:
Our earnings preview for Wednesday afternoon and Thursday morning includes a COVID-19 vaccine maker, a chipmaker and a company that designs and builds hydrogen fuel cells.
Published:
Here, 24/7 Wall St. has put together a preview of a few of the most anticipated quarterly reports due this week, including those from Airbnb, Best Buy, Home Depot, Moderna, Nvidia and Salesforce.
Published:
24/7 Wall St. has compiled a list of a few of the biggest movers along why they are moving, a recent trading history and what the consensus estimate is from analysts.
Published:
Monday's top analyst upgrades and downgrades included AMC Entertainment, Bed Bath & Beyond, Halliburton, Intuit, Moderna, Nikola, Phillips 66, Stitch Fix and Virgin Galactic.
Published:
The November 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Wednesday's top analyst calls included American Express, Apple, Baidu, CarMax, Chewy, Lululemon Athletica, Micron Technology, Moderna, Slack, Walt Disney and Zoom Video Communications.
Published:
Last Updated:
COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.
Published:
Moderna shares continued to run higher on Monday after the company announced an update for the primary efficacy analysis for its late-stage coronavirus vaccine trial.
Published:
The November 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Published:
Monday's top analyst upgrades and downgrades included Darden Restaurants, Foot Locker, Gap, Kellogg, Moderna, Philip Morris International, Prologis, Rockwell Automation and Texas Roadhouse.
Published: